A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding ...

SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

“As a two-time prostate cancer survivor, I enjoy today as if it will be my last,” Jesse said. “I engage every man I meet ...

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...

The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical recurrence, according to a study published ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

I’m a 64-year-old man who was recently diagnosed with an enlarged prostate after experiencing issues with frequent urination, ...

While the benefits of screening tests for cervical cancer, breast cancer, and colorectal cancer are widely accepted, screening for prostate cancer remains controversial to some. The main screening ...